Cited by 177Anxiety, Depression, Psychometrics, Treatment, Cognitive ProcessesTreatment of Major DepressionMaternal Mental Health During Pregnancy and Postpartum

The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.

Venlafaxine Extended Release (ER) in the Treatment of Generalised Anxiety Disorder: Twenty-four-week placebo-controlled dose-ranging study

Open access

Allgulander, Christer, Hackett, David, Salinas, Eliseo·2001·British Journal of Psychiatry

DOI 10.1192/bjp.179.1.15

Open this paper in CoChat — free account Open PDF

Abstract

Background: Generalised anxiety disorder (GAD) has received less study than other anxiety disorders, particularly its long-term treatment. Aims: To assess the efficacy and safety of venlafaxine extended release (ER) in patients with GAD. Method: A total of 541 out-patients, 18–86 years old, were recruited to this 24-week, placebo-controlled, double-blind study of three fixed doses (37.5, 75 and 150 mg/day) of venlafaxine ER. Results: All doses of venlafaxine ER showed efficacy superior to placebo, apparent from week 2, that was sustained throughout the 24-week study for the two higher doses. The discontinuation rate did not differ significantly among the treatment groups. Conclusions: Venlafaxine ER is an effective and safe treatment for GAD for up to 6 months.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1192/bjp.179.1.15

Cites

23 of 23 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Diagnostic and Statistical Manual of Mental Disorders
Williams, J. B. W., & First, M. B. (2013) · Oxford University Press eBooks · doi:10.1093/acrefore/9780199975839.013.104 · Cited by 109,845
The Hospital Anxiety and Depression Scale
Zigmond, A. S., & Snaith, R. P. (1983) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1983.tb09716.x · Cited by 47,139
The assessment of anxiety states by rating
HAMILTON, M. (1959) · British Journal of Medical Psychology · doi:10.1111/j.2044-8341.1959.tb00467.x · Cited by 11,455
Untitled work
(1976) · Medical Entomology and Zoology · Cited by 8,899
Assessment of social adjustment by patient self report.
Weissman, M. M. (1976) · Archives of General Psychiatry · doi:10.1001/archpsyc.1976.01770090101010 · Cited by 1,782
DSM-III-R Generalized Anxiety Disorder in the National Comorbidity Survey
Wittchen, H.-U. (1994) · Archives of General Psychiatry · doi:10.1001/archpsyc.1994.03950050015002 · Cited by 967
Selective serotonin reuptake inhibitor discontinuation syndrome: a randomized clinical trial
Rosenbaum, J. F., Fava, M., Hoog, S. L., Ascroft, R. C., & Krebs, W. B. (1998) · Biological Psychiatry · doi:10.1016/s0006-3223(98)00126-7 · Cited by 574
Antidepressants for the Treatment of Generalized Anxiety Disorder
Rickels, K. (1993) · Archives of General Psychiatry · doi:10.1001/archpsyc.1993.01820230054005 · Cited by 416
Buspirone
Goa, K. L., & Ward, A. (1986) · Drugs · doi:10.2165/00003495-198632020-00002 · Cited by 333
Long-term Therapeutic Use of Benzodiazepines: I. Effects of Abrupt Discontinuation
Rickels, K. (1990) · Archives of General Psychiatry · doi:10.1001/archpsyc.1990.01810220015002 · Cited by 332

Flagged first, then by citations

Show all 23 references

Research works printed but not linked: 2

1989, ‘COSTART’: Coding Symbols for Thesaurus of Adverse Reactions Terms
Kessler R. C. & Wittchen H. -U. (2001) GAD-associated impairment controlling for MDE in the NCS and MIDUS surveys. Psychological Medicine, in press

Sorted by citations

Canadian clinical practice guidelines for the management of anxiety, posttraumatic stress and obsessive-compulsive disorders
Katzman, M. A., Bleau, P., Blier, P., Chokka, P., Kjernisted, K., Van Ameringen, M., & the Canadian Anxiety Guidelines Initiative Group on behalf of the Anxiety Disorders Association of Canada/Association Canadienne des troubles anxieux and McGill University (2014) · BMC Psychiatry · doi:10.1186/1471-244x-14-s1-s1 · Cited by 1,090
The neurobiology and control of anxious states
Millan, M. J. (2003) · Progress in Neurobiology · doi:10.1016/s0301-0082(03)00087-x · Cited by 978
World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Pharmacological Treatment of Anxiety, Obsessive-Compulsive and Post-Traumatic Stress Disorders – First Revision
Bandelow, B., Zohar, J., Hollander, E., Kasper, S., Möller, H., & WFSBP Task Force on Treatment Guide (2008) · The World Journal of Biological Psychiatry · doi:10.1080/15622970802465807 · Cited by 887
Generalized anxiety disorder: prevalence, burden, and cost to society
Wittchen, H.-U. (2002) · Depression and Anxiety · doi:10.1002/da.10065 · Cited by 733
Evidence-based guidelines for the pharmacological treatment of anxiety disorders: recommendations from the British Association for Psychopharmacology
Baldwin, D. S., Anderson, I. M., Nutt, D. J., Bandelow, B., Bond, A., Davidson, J. R. T., den Boer, J. A., Fineberg, N. A., Knapp, M., Scott, J., et al. (2005) · Journal of Psychopharmacology · doi:10.1177/0269881105059253 · Cited by 617
SNRIs: The Pharmacology, Clinical Efficacy, and Tolerability in Comparison with Other Classes of Antidepressants
Stahl, S. M., Grady, M. M., Moret, C., & Briley, M. (2005) · CNS Spectrums · doi:10.1017/s1092852900019726 · Cited by 471
Acute and Persistent Withdrawal Syndromes Following Discontinuation of Psychotropic Medications
Cosci, F., & Chouinard, G. (2020) · Psychotherapy and Psychosomatics · doi:10.1159/000506868 · Cited by 265
Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for the treatment of panic disorder, social anxiety disorder and generalised anxiety disorder
Andrews, G., Bell, C., Boyce, P., Gale, C., Lampe, L., Marwat, O., Rapee, R., & Wilkins, G. (2018) · Australian & New Zealand Journal of Psychiatry · doi:10.1177/0004867418799453 · Cited by 243
Withdrawal Symptoms after Serotonin-Noradrenaline Reuptake Inhibitor Discontinuation: Systematic Review
Fava, G. A., Benasi, G., Lucente, M., Offidani, E., Cosci, F., & Guidi, J. (2018) · Psychotherapy and Psychosomatics · doi:10.1159/000491524 · Cited by 209
Efficacy and Safety of Extended-Release Venlafaxine in the Treatment of Generalized Anxiety Disorder in Children and Adolescents: Two Placebo-Controlled Trials
Rynn, M. A., Riddle, M. A., Yeung, P. P., & Kunz, N. R. (2007) · American Journal of Psychiatry · doi:10.1176/ajp.2007.164.2.290 · Cited by 185
An effect-size analysis of pharmacologic treatments for generalized anxiety disorder
Hidalgo, R. B., Tupler, L. A., & Davidson, J. R. T. (2007) · Journal of Psychopharmacology · doi:10.1177/0269881107076996 · Cited by 179
Evidence-based pharmacological treatment of generalized anxiety disorder
Baldwin, D. S., Waldman, S., & Allgulander, C. (2011) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145710001434 · Cited by 183
Self-citation
Efficacy of Pregabalin in the Treatment of Generalized Anxiety Disorder
Pohl, R. B., Feltner, D. E., Fieve, R. R., & Pande, A. C. (2005) · Journal of Clinical Psychopharmacology · doi:10.1097/01.jcp.0000155820.74832.b0 · Cited by 169
World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Pharmacological Treatment of Anxiety, Obsessive-Compulsive and Posttraumatic Stress Disorders
Bandelow, B., Zohar, J., Hollander, E., Kasper, S. F., Möller, H., & WFSBP Task Force on Treatment Guide (2002) · The World Journal of Biological Psychiatry · doi:10.3109/15622970209150621 · Cited by 170
Effects of citalopram on worry and brain activation in patients with generalized anxiety disorder
Hoehn‐Saric, R., Schlund, M. W., & Wong, S. H. (2004) · Psychiatry Research Neuroimaging · doi:10.1016/j.pscychresns.2004.02.003 · Cited by 167
Venlafaxine Extended Release vs Placebo and Paroxetine in Social Anxiety Disorder
Liebowitz, M. R., Gelenberg, A. J., & Munjack, D. J. (2005) · Archives of General Psychiatry · doi:10.1001/archpsyc.62.2.190 · Cited by 163
Antidepressants for generalised anxiety disorder (GAD)
Kapczinski, F. P., Souza, J. J. D. S., da Cunha, A. A. B. M., & Schmitt, R. R. (2003) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003592 · Cited by 163
Retracted
Cost-Effectiveness of Psychological and Pharmacological Interventions for Generalized Anxiety Disorder and Panic Disorder
Heuzenroeder, L., Donnelly, M., Haby, M. M., Mihalopoulos, C., Rossell, R., Carter, R., Andrews, G., & Vos, T. (2004) · Australian & New Zealand Journal of Psychiatry · doi:10.1080/j.1440-1614.2004.01423.x · Cited by 161
Venlafaxine Extended Release in Posttraumatic Stress Disorder: A Sertraline- and Placebo-controlled Study
Davidson, J., Rothbaum, B. O., Tucker, P., Asnis, G., Benattia, I., & Musgnung, J. J. (2006) · Journal of Clinical Psychopharmacology · doi:10.1097/01.jcp.0000222514.71390.c1 · Cited by 157
Psychological and pharmacological treatments for generalized anxiety disorder (GAD): a meta-analysis of randomized controlled trials
Carl, E., Witcraft, S. M., Kauffman, B. Y., Gillespie, E. M., Becker, E. S., Cuijpers, P., Van Ameringen, M., Smits, J. A. J., & Powers, M. B. (2020) · Cognitive Behaviour Therapy · doi:10.1080/16506073.2018.1560358 · Cited by 151
Anxiety disorders: a comprehensive review of pharmacotherapies
Hoffman, E. J., & Mathew, S. J. (2008) · Mount Sinai Journal of Medicine: A Journal of Translational and Personalized Medicine · doi:10.1002/msj.20041 · Cited by 149
Kava-Kava extract LI 150 is as effective as Opipramol and Buspirone in Generalised Anxiety Disorder – An 8-week randomized, double-blind multi-centre clinical trial in 129 out-patients
Boerner, R. J., Sommer, H., Berger, W. L., Kühn, U., Schmidt, U., & Mannel, M. (2003) · Phytomedicine · doi:10.1078/1433-187x-00309 · Cited by 141
Efficacy of Sertraline in a 12-Week Trial for Generalized Anxiety Disorder
Allgulander, C., Dahl, A. A., Austin, C., Morris, P., Søgaard, J., Fayyad, R. S., Kutcher, S., & Clary, C. M. (2004) · American Journal of Psychiatry · doi:10.1176/appi.ajp.161.9.1642 · Cited by 140
Self-citation
A Meta-analytic Review of the Efficacy of Drug Treatment in Generalized Anxiety Disorder
Mitte, K., Noack, P., Steil, R., & Hautzinger, M. (2005) · Journal of Clinical Psychopharmacology · doi:10.1097/01.jcp.0000155821.74832.f9 · Cited by 137
Systematic review and meta-analysis: dose-response curve of SSRIs and SNRIs in anxiety disorders
Jakubovski, E., Johnson, J. A., Nasir, M., Müller-Vahl, K., & Bloch, M. H. (2019) · Depression and Anxiety · doi:10.1002/da.22854 · Cited by 131
Prevention of relapse in generalized anxiety disorder by escitalopram treatment
Allgulander, C., Florea, I., & Huusom, A. K. T. (2005) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145705005973 · Cited by 130
Self-citation
Long-term efficacy of pregabalin in generalized anxiety disorder
Feltner, D. E., Wïttchen, H., Kavoussi, R. J., Brock, J., Baldinetti, F., & Pande, A. C. (2008) · International Clinical Psychopharmacology · doi:10.1097/yic.0b013e3282f0f0d7 · Cited by 130
Evidence-based pharmacotherapy of Generalized Anxiety Disorder
Baldwin, D. S., & Polkinghorn, C. (2005) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145704004870 · Cited by 132
Comparing the efficacy of benzodiazepines and serotonergic anti-depressants for adults with generalized anxiety disorder: A meta-analytic review
Gomez, A. F., Barthel, A. L., & Hofmann, S. G. (2018) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2018.1472767 · Cited by 125
Generalized anxiety disorder: comorbidity, comparative biology and treatment
Nutt, D., Ballenger, J. C., Sheehan, D. V., & Wïttchen, H. (2002) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145702003048 · Cited by 129
Advances in the treatment of depression
Holtzheimer, P. E., & Nemeroff, C. B. (2006) · NeuroRx · doi:10.1016/j.nurx.2005.12.007 · Cited by 119
Efficacy of Venlafaxine ER in patients with social anxiety disorder: a double‐blind, placebo‐controlled, parallel‐group comparison with paroxetine
Allgulander, C., Mangano, R. M., Zhang, J., Dahl, A. A., Lepola, U. M., Sjödin, I., & Emilien, G. (2004) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.602 · Cited by 113
Self-citation
Efficacy of low and higher dose extended-release venlafaxine in generalized social anxiety disorder: a 6-month randomized controlled trial
Stein, M. B., Pollack, M. H., Bystritsky, A., Kelsey, J. E., & Mangano, R. M. (2004) · Psychopharmacology · doi:10.1007/s00213-004-1957-9 · Cited by 110
A double-blind study of the efficacy of venlafaxine extended-release, paroxetine, and placebo in the treatment of panic disorder
Pollack, M. H., Lepola, U. M., Koponen, H., Simon, N. M., Worthington, J. J., Emilien, G., Tzanis, E. L., Salinas, E. O., Whitaker, T., & Gao, B. (2006) · Depression and Anxiety · doi:10.1002/da.20218 · Cited by 104
Self-citation
Venlafaxine: A 2003 update
Gutierrez, M. A., Stimmel, G. L., & Aiso, J. Y. (2003) · Clinical Therapeutics · doi:10.1016/s0149-2918(03)80210-2 · Cited by 101
Structural and functional neuroimaging studies in generalized anxiety disorder: a systematic review
Madonna, D., Delvecchio, G., Soares, J. C., & Brambilla, P. (2019) · Brazilian Journal of Psychiatry · doi:10.1590/1516-4446-2018-0108 · Cited by 103
A Double-Blind, Placebo-Controlled Study of a Flexible Dose of Venlafaxine ER in Adult Outpatients With Generalized Social Anxiety Disorder
Rickels, K., Mangano, R. M., & Khan, A. (2004) · Journal of Clinical Psychopharmacology · doi:10.1097/01.jcp.0000138764.31106.60 · Cited by 98
Efficacy of pregabalin and venlafaxine-XR in generalized anxiety disorder: results of a double-blind, placebo-controlled 8-week trial
Kasper, S. F., Herman, B. K., Nivoli, G., Ameringen, M. V., Petralia, A., Mandel, F. S., Baldinetti, F., & Bandelow, B. (2009) · International Clinical Psychopharmacology · doi:10.1097/yic.0b013e32831d7980 · Cited by 98
Serotonin norepinephrine reuptake inhibitors (SNRIs) in anxiety disorders: a comprehensive review of their clinical efficacy
Dell’Osso, B. M., Buoli, M., Baldwin, D. S., & Altamura, A. C. (2009) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.1074 · Cited by 94
The effects of venlafaxine and cognitive behavioral therapy alone and combined in the treatment of co-morbid alcohol use-anxiety disorders
Ciraulo, D. A., Barlow, D. H., Gulliver, S. B., Farchione, T. J., Morissette, S. B., Kamholz, B. W., Eisenmenger, K., Brown, B., Devine, E. G., Brown, T. A., et al. (2013) · Behaviour Research and Therapy · doi:10.1016/j.brat.2013.08.003 · Cited by 92
WCA Recommendations for the Long-Term Treatment of Generalized Anxiety Disorder
Allgulander, C., Bandelow, B., Hollander, E., Montgomery, S., Nutt, D., Okasha, A., Pollack, M. H., Stein, D. J., & Swinson, R. P. (2003) · CNS Spectrums · doi:10.1017/s1092852900006945 · Cited by 92
Self-citation
Pregabalin for the treatment of generalized anxiety disorder: a novel pharmacologic intervention
Bandelow, B., Wedekind, D., & León, T. (2007) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.7.7.769 · Cited by 85
The Diagnosis and Treatment of Generalized Anxiety Disorder
Bandelow, B., Boerner, R. J., Kasper, S. F., Linden, M., Wïttchen, H., & Möller, H. (2013) · Deutsches Ärzteblatt international · doi:10.3238/arztebl.2013.0300 · Cited by 93
Overuse of Antidepressant Drugs for the Treatment of Depression
Jureidini, J. N., & Tonkin, A. (2006) · CNS Drugs · doi:10.2165/00023210-200620080-00002 · Cited by 81
Quetiapine monotherapy in acute treatment of generalized anxiety disorder: a systematic review and meta-analysis of randomized controlled trials
Maneeton, N., Maneeton, B., Woottiluk, P., Likhitsathian, S., Suttajit, S., Boonyanaruthee, V., & Srisurapanont, M. (2016) · Drug Design Development and Therapy · doi:10.2147/dddt.s89485 · Cited by 82
Venlafaxine extended release versus conventional antidepressants in the remission of depressive disorders after previous antidepressant failure: ARGOS study
Baldomero, E. B., Ubago, J. G., Cercós, C. L., Ruiloba, J. V., Calvo, C. G., Lopez, R., & for the ARGOS Study Group (2005) · Depression and Anxiety · doi:10.1002/da.20080 · Cited by 75
Generalized Anxiety Disorder: Acute and Chronic Treatment
Rynn, M. A., & Brawman‐Mintzer, O. (2004) · CNS Spectrums · doi:10.1017/s1092852900022367 · Cited by 75
A randomized controlled trial of venlafaxine ER and paroxetine in the treatment of outpatients with panic disorder
Pollack, M. H., Mangano, R. M., Entsuah, R., Tzanis, E. L., & Simon, N. M. (2007) · Psychopharmacology · doi:10.1007/s00213-007-0821-0 · Cited by 73
Vortioxetine (Lu AA21004) in generalized anxiety disorder: Results of an 8-week, multinational, randomized, double-blind, placebo-controlled clinical trial
Bidzan, L., Mahableshwarkar, A. R., Jacobsen, P. L., Yan, M., & Sheehan, D. V. (2012) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2012.07.012 · Cited by 72
Venlafaxine Versus Placebo in the Preventive Treatment of Recurrent Major Depression
Montgomery, S., Entsuah, R., Hackett, D., Kunz, N. R., Rudolph, R. L., & Venlafaxine 335 Study Group (2004) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v65n0307 · Cited by 69
Self-citation
Characterization of the longitudinal course of improvement in generalized anxiety disorder during long-term treatment with venlafaxine XR
Montgomery, S., Sheehan, D. V., Meoni, P., Haudiquet, V., & Hackett, D. (2002) · Journal of Psychiatric Research · doi:10.1016/s0022-3956(02)00005-5 · Cited by 68
Self-citation
The pharmacological management of childhood anxiety disorders: a review
Reinblatt, S. P., & Riddle, M. A. (2007) · Psychopharmacology · doi:10.1007/s00213-006-0644-4 · Cited by 67
Review: A psychopharmacological treatment algorithm for generalised anxiety disorder (GAD)
Davidson, J., Zhang, W., Connor, K., Ji, J., Jobson, K. O., Lecrubier, Y., McFARLANE, A. C., Newport, D. J., Nutt, D., Osser, D. N., et al. (2008) · Journal of Psychopharmacology · doi:10.1177/0269881108096505 · Cited by 67
Anxiety disorders in older adults
Lauderdale, S. A., & Sheikh, J. I. (2003) · Clinics in Geriatric Medicine · doi:10.1016/s0749-0690(03)00047-8 · Cited by 61
Physician Withdrawal Checklist (PWC-20)
Rickels, K., Garcia-Espana, F., Mandos, L. A., & Case, G. W. (2008) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e31817efbac · Cited by 59
Anxiety Symptoms and Generalized Anxiety Disorder in the Elderly: A Review
Alwahhabi, F. (2003) · Harvard Review of Psychiatry · doi:10.1080/10673220303944 · Cited by 62
A double-blind, randomised, placebo controlled study of venlafaxine XL in patients with generalised anxiety disorder in primary care.
Lenox‐Smith, A., & Reynolds, A. (2003) · Europe PMC (PubMed Central) · Cited by 58
Treatment-Resistant Panic Disorder
Bandelow, B., & Rüther, E. (2004) · CNS Spectrums · doi:10.1017/s1092852900022379 · Cited by 57
Management of Generalized Anxiety Disorder in Primary Care
Davidson, J. R. T., Feltner, D. E., & Dugar, A. (2010) · The Primary Care Companion to The Journal of Clinical Psychiatry · doi:10.4088/pcc.09r00772blu · Cited by 56
Gender differences in clinical presentation and response to sertraline treatment of generalized anxiety disorder
Steiner, M. S., Allgulander, C., Ravindran, A. V., Kosar, H., Burt, T., & Austin, C. (2004) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.648 · Cited by 59
Self-citation
Randomized placebo-controlled trial of escitalopram and venlafaxine XR in the treatment of generalized anxiety disorder
Bose, A., Korotzer, A. R., Gommoll, C., & Li, D. (2007) · Depression and Anxiety · doi:10.1002/da.20355 · Cited by 53
A Review of the Diagnosis, Pharmacologic Treatment, and Economic Aspects of Anxiety Disorders
Arikian, S. R., & Gorman, J. M. (2001) · The Primary Care Companion For CNS Disorders · doi:10.4088/pcc.v03n0302 · Cited by 53
Defining Response and Remission in Anxiety Disorders: Toward an Integrated Approach
Bandelow, B. (2006) · CNS Spectrums · doi:10.1017/s1092852900025815 · Cited by 52
Generalized anxiety disorder publications: where do we stand a decade later?
Dugas, M. J., Anderson, K. G., Deschênes, S., & Donegan, E. (2010) · Journal of Anxiety Disorders · doi:10.1016/j.janxdis.2010.05.012 · Cited by 59
Meta-analysis: Risk of dry mouth with second generation antidepressants
Cappetta, K., Beyer, C., Johnson, J. A., & Bloch, M. H. (2018) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2017.12.012 · Cited by 49
The efficacy of antidepressants for generalized anxiety disorder: a systematic review and meta-analysis
Schmitt, R. L. D. S., Gazalle, F. K., de Lima, M. S., Cunha, A. B. M., Souza, J. S., & Kapczinski, F. P. (2005) · Brazilian Journal of Psychiatry · doi:10.1590/s1516-44462005000100007 · Cited by 48
Efficacy and safety of duloxetine in the treatment of older adult patients with generalized anxiety disorder: a randomized, double‐blind, placebo‐controlled trial
Alaka, K., Noble, W. C., Montejo, A. L., Dueñas, H., Munshi, A., Strawn, J. R., Lenox‐Smith, A., AHL, J. S. B., Bidzan, L., Dorn, B., et al. (2014) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.4088 · Cited by 48
Remission rates with venlafaxine extended release in Greek outpatients with generalized anxiety disorder. A double-blind, randomized, placebo controlled study
Nimatoudis, I., Zissis, N. P., Kogeorgos, J., Theodoropoulou, S., Vidalis, A. A., & KAPRINIS, G. S. (2004) · International Clinical Psychopharmacology · doi:10.1097/00004850-200411000-00003 · Cited by 47
A method for controlling for a high placebo response rate in a comparison of venlafaxine XR and diazepam in the short-term treatment of patients with generalised anxiety disorder
Hackett, D., Haudiquet, V., & Salinas, E. O. (2003) · European Psychiatry · doi:10.1016/s0924-9338(03)00046-4 · Cited by 47
Self-citation
Pharmacological Treatments for Worry: Focus on Generalised Anxiety Disorder
Anderson, I. M., & Palm, M. E. (2006) · Wiley eBooks · doi:10.1002/9780470713143.ch18 · Cited by 45
A DOUBLE‐BLIND, RANDOMIZED, PLACEBO‐CONTROLLED, FIXED‐DOSE PHASE III STUDY OF VILAZODONE IN PATIENTS WITH GENERALIZED ANXIETY DISORDER
Gommoll, C., Durgam, S., Mathews, M., Forero, G., Núñez, R., Tang, X., & Thase, M. E. (2015) · Depression and Anxiety · doi:10.1002/da.22365 · Cited by 44
Escitalopram in the treatment of generalized anxiety disorder
Baldwin, D. S., & Nair, R. V. (2005) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.5.4.443 · Cited by 42
Onset of activity and time to response on individual CAPS-SX17 items in patients treated for post-traumatic stress disorder with venlafaxine ER: a pooled analysis
Stein, D. J., Pedersen, R., ROTHBAUM, B. O., Baldwin, D. S., Ahmed, S., Musgnung, J. J., & Davidson, J. R. T. (2008) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145708008961 · Cited by 41
Validating the inhalation of 7.5% CO 2 in healthy volunteers as a human experimental medicine: a model of generalized anxiety disorder (GAD)
Bailey, J., Dawson, G. R., Dourish, C. T., & Nutt, D. (2011) · Journal of Psychopharmacology · doi:10.1177/0269881111408455 · Cited by 41
Depression in relation to anxiety, obsessionality and phobia among neurosurgical patients with a primary brain tumor: A 1-year follow-up study
Mainio, A., Hakko, H. H., Niemelä, A., Koivukangas, J. P., & Räsänen, P. K. (2011) · Clinical Neurology and Neurosurgery · doi:10.1016/j.clineuro.2011.05.006 · Cited by 40
Incidence and Nature of Antidepressant Discontinuation Symptoms
Kalfas, M., Tsapekos, D., Butler, M., McCutcheon, R. A., Pillinger, T., Strawbridge, R., Bhat, B. B., Haddad, P. M., Cowen, P. J., Howes, O. D., et al. (2025) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2025.1362 · Cited by 42
Pharmacological Treatment of Generalized Anxiety Disorder
Baldwin, D. S., Ajel, K. I., & Garner, M. J. (2009) · Current topics in behavioral neurosciences · doi:10.1007/7854_2009_2 · Cited by 39
Sertraline in generalized anxiety disorder: efficacy in treating the psychic and somatic anxiety factors
Dahl, A. A., Ravindran, A. V., Allgulander, C., Kutcher, S., Austin, C., & Burt, T. (2005) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.2005.00529.x · Cited by 39
Self-citation
Predictors of Outcome Following Venlafaxine Extended-Release Treatment of DSM-IV Generalized Anxiety Disorder: A Pooled Analysis of Short- and Long-Term Studies
Pollack, M. H., Meoni, P., Otto, M. W., & Hackett, D. (2003) · Journal of Clinical Psychopharmacology · doi:10.1097/01.jcp.0000084025.22282.84 · Cited by 38
Self-citation
Long-term treatment of anxiety disorders with pregabalin: a 1 year open-label study of safety and tolerability
Montgomery, S., Emir, B., Haswell, H., & Prieto, R. (2013) · Current Medical Research and Opinion · doi:10.1185/03007995.2013.820694 · Cited by 36
Treatment of anxiety disorders with venlafaxine XR
Thase, M. E. (2006) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.6.3.269 · Cited by 37
Pharmacotherapy of Anxiety
Nash, J. R., & Nutt, D. (2005) · Handbook of experimental pharmacology · doi:10.1007/3-540-28082-0_17 · Cited by 32
Long-term goals in the management of acute and chronic anxiety disorders.
Kjernisted, K. D., & Bleau, P. (2004) · PubMed · Cited by 29
Evidence-Based Review of Clinical Outcomes of Guideline-Recommended Pharmacotherapies for Generalized Anxiety Disorder
Bereza, B. G., Machado, M., Ravindran, A. V., & Einarson, T. R. (2012) · The Canadian Journal of Psychiatry · doi:10.1177/070674371205700805 · Cited by 29
Establishing non-inferiority in treatment trials in psychiatry — guidelines from an Expert Consensus Meeting
Nutt, D., Allgulander, C., Lecrubier, Y., Peters, T., & Wïttchen, H. (2008) · Journal of Psychopharmacology · doi:10.1177/0269881108091068 · Cited by 28
Self-citation
Emerging treatments for depression
Holtzheimer, P. E., & Nemeroff, C. B. (2006) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.7.17.2323 · Cited by 27
Qualitative review of SNRIs in anxiety.
Silverstone, P. H. (2004) · PubMed · Cited by 26
Development of SPECT imaging agents for the norepinephrine transporters: [123I]INER
Tamagnan, G. D., Brenner, E., Alagille, D., Staley, J. K., Haile, C. N., Koren, A. O., Early, M., Baldwin, R. M., Tarazi, F. I., Baldessarini, R. J., et al. (2006) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2006.10.018 · Cited by 25
Duloxetine in the treatment of generalized anxiety disorder
Kornstein, S. G., Russell, J. M., Spann, M. E., Crits-Christoph, P. F., & Ball, S. G. (2009) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.9.2.155 · Cited by 25
Serotonin noradrenaline reuptake inhibitors: A new generation of treatment for anxiety disorders
Baldwin, D. S. (2006) · International Journal of Psychiatry in Clinical Practice · doi:10.1080/13651500600637056 · Cited by 26
Venlafaxine versus Mirtazapine in the??Treatment of Undifferentiated Somatoform Disorder
Han, C., Pae, C.-U., Lee, B. H., Ko, Y., Masand, P. S., Patkar, A. A., Joe, S., & Jung, I. K. (2008) · Clinical Drug Investigation · doi:10.2165/00044011-200828040-00006 · Cited by 24
Long term therapy of generalized anxiety disorder
Rouillon, F. (2004) · European Psychiatry · doi:10.1016/j.eurpsy.2004.01.001 · Cited by 24
Meta-analysis: Risk of hyperhidrosis with second-generation antidepressants
Beyer, C., Cappetta, K., Johnson, J. A., & Bloch, M. H. (2017) · Depression and Anxiety · doi:10.1002/da.22680 · Cited by 24
Treatments for generalized anxiety disorder
Struzik, L., Vermani, M., Coonerty-Femiano, A., & Katzman, M. A. (2004) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.4.2.285 · Cited by 23
Analysis of the Rate of Improvement of Specific Psychic and Somatic Symptoms of General Anxiety Disorder During Long-Term Treatment with Venlafaxine ER
Stahl, S. M., Ahmed, S., & Haudiquet, V. (2007) · CNS Spectrums · doi:10.1017/s1092852900021544 · Cited by 21
Open-Label Evaluation of Venlafaxine Sustained Release in Outpatients with Generalized Anxiety Disorder with Comorbid Major Depression or Dysthymia: Effectiveness, Tolerability and Predictors of Response
Perugi, G., Frare, F., Toni, C., Ruffolo, G., & Torti, C. (2002) · Neuropsychobiology · doi:10.1159/000066391 · Cited by 21
Effectiveness of Venlafaxine, Extended Release Formulation, in the Short-Term and Long-Term Treatment of Generalized Anxiety Disorder: Results of a Survival Analysis
Montgomery, S., Mahé, V., Haudiquet, V., & Hackett, D. (2002) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-200212000-00005 · Cited by 21
Self-citation
The Neurotherapy of Anxiety Disorders
Moore, N. C. (2005) · Journal of Adult Development · doi:10.1007/s10804-005-7031-y · Cited by 20
Therapeutic Implications of microRNAs in Depressive Disorders: A Review
Hassan, M., Amir, A., Shahzadi, S., & Kloczkowski, A. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232113530 · Cited by 21
Venlafaxine in the treatment of anxiety disorders
Katzman, M. A. (2004) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.4.3.371 · Cited by 18

Authors: Allgulander, C., Hackett, D., & Salinas, E.
Corresponding author: Allgulander, Christer
Venue: British Journal of Psychiatry
Publisher: Royal College of Psychiatrists
Published: 2001-07
Volume: 179
Issue: 1
Pages: 15-22
ISSN: 0007-1250 (ISSN-L)
1472-1465
DOI: 10.1192/bjp.179.1.15
OpenAlex: W2122087038
Cited by: 175
References: 23
Citations by year: 2026: 3 · 2025: 2 · 2024: 4 · 2023: 2 · 2022: 4 · 2021: 1 · 2020: 3 · 2019: 4 · 2018: 4 · 2017: 3 · 2016: 3 · 2015: 2 · 2014: 3 · 2013: 7 · 2012: 5
FWCI: 25.99
Type: journal article
Language: en
Open access: bronze
doi.org
Licence: www.cambridge.org/core/terms (unspecified, 6029 d)
Locations: The British Journal of Psychiatry (publishedVersion)
PubMed (publishedVersion)
Funders: Karolinska Institutet
Topics: Social Sciences › Psychology › Experimental and Cognitive Psychology › Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Maternal Mental Health During Pregnancy and Postpartum
Keywords: venlafaxine extended release, generalized anxiety disorder, antidepressant efficacy, drug safety, long-term treatment, dose comparison, treatment discontinuation
MeSH terms: Venlafaxine Hydrochloride, Adolescent, Adult, Aged, Aged, 80 and over, Anxiety Disorders, Chronic Disease, Cyclohexanols, Delayed-Action Preparations, Double-Blind Method, Female, Humans, Male, Middle Aged, Psychiatric Status Rating Scales, Antidepressive Agents, Second-Generation

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Venlafaxine Extended Release (ER) in the Treatment of Generalised Anxiety Disorder: Twenty-four-week placebo-controlled dose-ranging study

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks